Pharmacokinetics

被引:225
作者
Fan, Jianghong [1 ]
de Lannoy, Ines A. M. [1 ]
机构
[1] InterVivo Solut Inc, Toronto, ON M5A 4K2, Canada
关键词
Pharmacokinetics; Absorption; Distribution; Clearance; Metabolite kinetics; Pharmacodynamics; BLOOD-BRAIN-BARRIER; VITRO METABOLIC-CLEARANCE; INDIRECT RESPONSE MODELS; PLASMA-PROTEIN BINDING; DRUG-DRUG INTERACTION; IN-VIVO; ALDEHYDE OXIDASE; P-GLYCOPROTEIN; CLINICAL PHARMACOKINETICS; PHARMACODYNAMIC MODELS;
D O I
10.1016/j.bcp.2013.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics (PK) is the study of the time course of the absorption, distribution, metabolism and excretion (ADME) of a drug, compound or new chemical entity (NCE) after its administration to the body. Following a brief introduction as to why knowledge of the PK properties of an NCE is critical to its selection as a lead candidate in a drug discovery program and/or its use as a functional research tool, the present article presents an overview of PK principles, including practical guidelines for conducting PK studies as well as the equations required for characterizing and understanding the PK of an NCE and its metabolite(s). A review of the determination of in vivo PK parameters by non-compartmental and compartmental methods is followed by a brief overview of allometric scaling. Compound absorption and permeability are discussed in the context of intestinal absorption and brain penetration. The volume of distribution and plasma protein and tissue binding are covered as is the clearance (systemic, hepatic, renal, binary) of both small and large molecules. A section on metabolite kinetics describes how to estimate the PK parameters of a metabolite following administration of an NCE. Lastly, mathematical models used to describe pharmacodynamics (PD), the relationship between the NCE/compound concentration at the site of action and the resulting effect, are reviewed and linked to PK models in a section on PK/PD. (C) 2013 Published by Elsevier Inc.
引用
收藏
页码:93 / 120
页数:28
相关论文
共 153 条
[1]   Astrocyte-endothelial interactions at the blood-brain barrier [J].
Abbott, NJ ;
Rönnbäck, L ;
Hansson, E .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (01) :41-53
[2]   The integration of pharmacokinetics and pharmacodynamics: Understanding dose-response [J].
Abdel-Rahman, SM ;
Kauffman, RE .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 :111-136
[3]  
Abdou H., 1989, DISSOLUTION BIOAVAIL
[4]   CLINICAL PHARMACOKINETICS OF RIFAMPICIN [J].
ACOCELLA, G .
CLINICAL PHARMACOKINETICS, 1978, 3 (02) :108-127
[5]   Preparation and in vivo evaluation of a water-soluble prodrug for 2R-γ-tocotrienol and as a two-step prodrug for 2,7,8-trimethyl-2S-(β-carboxyethyl)-6-hydroxychroman (S-γ-CEHC) in rat [J].
Akaho, Nami ;
Takata, Jiro ;
Fukushima, Takeshi ;
Matsunaga, Kazuhisa ;
Hattori, Akihiro ;
Hidaka, Ryoji ;
Fukui, Kosuke ;
Yoshida, Miyako ;
Fujioka, Toshihiro ;
Karube, Yoshiharu ;
Imai, Kazuhiro .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1502-1510
[6]   The potential influence of CO2, as an agent for euthanasia, on the pharmacokinetics of basic compounds in rodents [J].
Angus, Derek W. ;
Baker, James A. ;
Mason, Rona ;
Martin, Iain J. .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :375-379
[7]  
[Anonymous], 2008, GUIDANCE IND SAFETY
[8]  
[Anonymous], [No title captured]
[9]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[10]  
ARTURSSON P, 1991, CRIT REV THER DRUG, V8, P305